NF-κB: A Druggable Target in Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) is an aggressive hematological malignancy that relies on highly heterogeneous cytogenetic alterations. Although in the last few years new agents have been developed for AML treatment, the overall survival prospects for AML patients are still gloomy and new therapeutic op...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-07, Vol.14 (14), p.3557
Main Authors: Di Francesco, Barbara, Verzella, Daniela, Capece, Daria, Vecchiotti, Davide, Di Vito Nolfi, Mauro, Flati, Irene, Cornice, Jessica, Di Padova, Monica, Angelucci, Adriano, Alesse, Edoardo, Zazzeroni, Francesca
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
Apoptosis
Cell cycle
Cell survival
Chemoresistance
Chemotherapy
Clinical outcomes
Cytogenetics
Cytokines
Genes
Hematological diseases
Kinases
Leukemia
Lymphoma
Malignancy
Medical prognosis
Mutation
NF-κB protein
Pathogenesis
Patients
Phosphorylation
Proteins
Review
Stem cells
Transcription factors
Tumor necrosis factor-TNF
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute Myeloid Leukemia (AML) is an aggressive hematological malignancy that relies on highly heterogeneous cytogenetic alterations. Although in the last few years new agents have been developed for AML treatment, the overall survival prospects for AML patients are still gloomy and new therapeutic options are still urgently needed. Constitutive NF-κB activation has been reported in around 40% of AML patients, where it sustains AML cell survival and chemoresistance. Given the central role of NF-κB in AML, targeting the NF-κB pathway represents an attractive strategy to treat AML. This review focuses on current knowledge of NF-κB's roles in AML pathogenesis and summarizes the main therapeutic approaches used to treat NF-κB-driven AML.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14143557